13 results on '"Meadows, Kristen Taylor"'
Search Results
2. DDDR-37. GB5121 IS A NOVEL, IRREVERSIBLE, COVALENT BTK INHIBITOR WITH HIGH SELECTIVITY AND CNS-PENETRANCE FOR TREATMENT OF CNS MALIGNANCIES
3. BSCI-11 GB5121 IS A NOVEL, IRREVERSIBLE, COVALENT BTK INHIBITOR WITH HIGH SELECTIVITY AND CNS-PENETRANCE FOR TREATMENT OF CNS MALIGNANCIES
4. Abstract 3330: GB5121 is a novel highly potent and selective CNS-penetrant BTK inhibitor for CNS malignancies
5. Editorial: protecting hypoxia‐inducible factor 1a and gut integrity with GB 004—a promising therapeutic approach for ulcerative colitis? Authors' reply
6. Fr150 GB004 EXHIBITS PROTECTIVE EFFECTS DIRECTLY ON EPITHELIAL CELLS USING EX VIVO ORGANOID AND MONOLAYER CULTURES
7. Tu1882 GB004, A NOVEL PROLYL HYDROXYLASE INHIBITOR FOR INFLAMMATOYR BOWEL DISEASE, LEADS TO GUT-TARGETED HIF-1ALPHA PATHWAY ENGAGEMENT IN A MULTIPLE DOSE STUDY IN HEATHY SUBJECTS
8. Mo1105 GB004, A NOVEL GUT-TARGETED PROLYL HYDROXYLASE INHIBITOR, INDUCES HIF-1ALPHA TARGET GENES AND IS EFFICACIOUS IN MOUSE COLITIS
9. P066 GB004, A NOVEL GUT-TARGETED PROLYL HYDROXYLASE INHIBITOR FOR INFLAMMATORY BOWEL DISEASE: FIRST-IN-HUMAN, MUTLIPLE-DOSE STUDY IN HEALTHY SUBJECTS WITH GUT BIOPSIES
10. In Vitro and In Vivo Profile of GB001, a Potent and Selective DP2 Antagonist for the Treatment of Moderate-Severe Asthma
11. Ozanimod (RPC1063) Reduces Plasma Levels of Neurofilament Light Chain (NfL) in Patients With Relapsing Multiple Sclerosis (RMS): Results From RADIANCE Part A, a Randomized, Placebo-Controlled, Phase 2 Study (P3.395)
12. Ozanimod (RPC1063) Preserves Central Nervous System (CNS) Tissue in Rodents by Reducing Neuronal Breaks in Vivo and Modulating Astrocyte Activity in Vitro (P5.027)
13. Editorial: protecting hypoxia‐inducible factor 1a and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis? Authors' reply.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.